glp 1 drugs and gastroparesis Researchers find GLP-1 medications safe to continue before surgery in patients with diabetes obesity Incidence of Gastroparesis with GLP-1

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 17 trials

Anyone researching retatrutide dosing or tracking the availability of retatrutide should factor hair loss risk into their consideration

Treatment starts with a lower dose of tirzepatide, gradually increasing to reach weight loss and health goals

These findings align with larger clinical trials

When blood sugar is low, GIP can actually increase glucagon secretion, which helps prevent hypoglycemia

Anekwe, MD, MPH, PNS, Instructor in Medicine, Harvard Medical School, Obesity Medicine Clinical Director, Massachusetts General Hospital